Organon (OGN) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Organon Reports Results for the Third Quarter Ended September 30, 2021
November 11, 2021 6:31 AM ESTThird quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424Â million, or $1.67 per diluted share Adjusted EBITDA of $636Â million Board of Directors declares quarterly dividend of $0.28 per share Financial guidance affirmed;Â ranges for revenue and Adjusted EBITDA margin, narrowed Executing on business development; announces acquisition of Forendo Pharma
JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) (the company), today announced its results for the third quarter and year to... More
